Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
103P - Stereotactic body radiotherapy followed by radiofrequency ablation for inoperable stage Ib non-small cell lung cancer (ID 169)
12:30 - 13:00 | Presenting Author(s): H. Ding
Hypoxia in the center of large tumor directly leads to radiation resistance. Concurrently, heat loss results in incomplete ablation oflarge tumors abutting airways or blood vessels. The combining stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) for non-small cell lung cancer (NSCLC) treatment could overcome respective shortcoming.
In this study, we report our experience with combined SBRT and RFA in 27 medically inoperable patients with biopsy-proven T2aN0M0 NSCLC. Patients were treated with SBRT to a dose of 50 Gy followed by CT-guided RFA within 7 days.
There were no treatment-related deaths. At a mean follow-up period of 29.6 months (range, 3 to 56 months), 15 patients (55.6%) died, with 1-year, 2-year, and 3-year cumulative survival rates of 77.8%, 63.0% and 48.1%, respectively. Threeof the deaths were cancer related. Four (14.8%) and five (18.5%) patients had local and distant recurrence, respectively.
We concluded that SBRT followed by RFA appears effective for centrally located NSCLC. Survival rates appear to be better than with SBRT or RFA alone. Interactions between the two modalities warrants deeper investigation.
Clinical trial identification:
Legal entity responsible for the study:
Has not received any funding
All authors have declared no conflicts of interest.